SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs admission of an affair and Nvidias independent investigation into reports that he was targeted by an alleged Chinese intelligence asset dominate discussion, with traders debating potential national-security and leadership risks. Bears fear fallout despite no confirmed compromise of company secrets, while bulls view the controversy as separate from Nvidias business and a buying opportunity.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,109,371. The last known price of Bitcoin is 75,663.53857906 USD and is down -0.17 over the last 24 hours. It is currently trading on 12776 active market(s) with $9,277,191,640.33 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff through closely watched support levels has fueled concern about further declines, with traders pointing to heavy selling and leveraged liquidations. The community is split between expecting a deeper breakdown and viewing the drop as a buying opportunity or bear trap, while proposed links to broader market weakness and geopolitical headlines remain speculative.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.16094256 USD and is down -1.49 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,342,393,155.38 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs steep decline alongside a broader crypto selloff is driving discussion, with traders watching the $1.10$1.20 area and debating whether it will hold. Some see the pullback as a buying opportunity, while others expect further losses; political uncertainty around crypto policy is also cited speculatively.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,197,894.00927157. The last known price of Ethereum is 2,232.83367397 USD and is down -0.19 over the last 24 hours. It is currently trading on 14283 active market(s) with $3,862,469,414.23 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is under pressure in a broad crypto selloff, with traders pointing to leveraged-long liquidations and wider risk-off sentiment; political and regulatory concerns are also cited, though their role is speculative. Bearish traders warn of further downside, while others are buying the dip and treating the decline as an accumulation opportunity.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,505.193803. The last known price of Zebec Network is 0.00179872 USD and is down -2.92 over the last 24 hours. It is currently trading on 133 active market(s) with $9,820,670.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Attention centers on Zebecs payroll and payments expansion, including MoneyGram/Stellar and European deployment developments, with traders debating whether growing adoption will translate into demand for ZBCN. Robinhood and Ripple-related claims are also fueling speculation, while skeptics point to weak price performance and question the tokens value capture.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

NNE is rebounding alongside other heavily sold-off small modular reactor stocks, prompting dip-buying and speculation about an oversold bounce or short covering. The community remains divided, with bullish traders citing nuclear power demand while skeptics point to the sectors prolonged slide and NNEs early-stage, pre-revenue profile.

Toshi (TOSHI) is a cryptocurrency launched in 2023and operates on the BNB Smart Chain (BEP20) platform. Toshi has a current supply of 420,689,980,957.1672248 with 420,658,160,155.40041346 in circulation. The last known price of Toshi is 0.00009751 USD and is down -1.72 over the last 24 hours. It is currently trading on 271 active market(s) with $2,368,303.26 traded over the last 24 hours. More information can be found at https://www.toshithecat.com/.

TOSHI

Dip-buying and hopes for a turnaround dominate TOSHI discussion, with holders adding after a prolonged decline while skeptics warn that further lows are possible. Traders are watching volume and chart resistance for a breakout, but no confirmed catalyst is driving the conversation.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases sharp post-earnings selloff is the main focus, with traders citing weaker crypto trading activity and a Morgan Stanley downgrade; falling crypto prices and fallout fears from the Binance hack add pressure. The community is split between bearish concerns about demand and risk and dip-buyers arguing Coinbase could gain users or recover with crypto markets.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a sharp technology-sector correction and concerns that heavy AI and data-center spending may not generate adequate returns, alongside put-heavy options activity. Traders are split between expecting further weakness and viewing the pullback as a buying opportunity, with some describing it as sector rotation rather than a broader market breakdown.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics Q3 results and whether BRIUMVIs rapid sales growth can support its outlook; traders are also watching for updates on the subcutaneous BRIUMVI program. Many are bullish on the growth and speculate about a buyout or short squeeze, while others warn that expectations are elevated and strong results may already be priced in.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application

Equity

The FDA cited concerns that the controlled phase advance protocols used in studies do not fully replicate real-world jet travel conditions.

Why Did Ironwood Pharmaceuticals Stock Skyrocket Today?

The company announced on Friday that it expects FY2026 revenue in the $450 million to $475 million range. 


SPDR Series Trust - State Street SPDR US Small Cap Low Volatility Index ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Vanda said it disagrees with the FDA assessment, noting that phase-advance models are widely accepted in circadian rhythm research.</li><li>The company emphasized Tasimelteon’s well-established safety profile.&nbsp;</li><li>The company had recently received FDA approval for NEREUS (Tradipitant), a motion-sickness treatment aimed at preventing vomiting.</li></ul>Shares of Vanda Pharmaceuticals Inc. (VNDA) fell 10% in premarket trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) stated that its supplemental New Drug Application for HETLIOZ (tasimelteon) to treat jet lag disorder cannot be approved in its current form.While the FDA acknowledged positive results from Vanda’s clinical trials, it cited concerns that the controlled phase-advance protocols used in the studies do not fully replicate real-world jet travel conditions, including reduced oxygen pressure, noise, and lighting changes.Vanda said it disagrees with the FDA assessment, noting that phase-advance models are widely accepted in circadian rhythm research and effectively simulate core jet-lag symptoms. The company emphasized tasimelteon’s well-established safety profile and demonstrated benefits on sleep and next-day alertness.This comes after the company received FDA approval for NEREUS (Tradipitant), a motion-sickness treatment aimed at preventing vomiting on December 31, 2025.The FDA approval marked the first new pharmacologic treatment for motion sickness in more than 40 years. Vanda expects to launch NEREUS in the coming months. Beyond motion sickness, Vanda is advancing tradipitant in clinical development for other conditions driven by similar pathways, including gastroparesis and nausea linked to GLP-1 therapies.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday decline, retail sentiment on Stocktwits turned 'bullish' from 'neutral' a day earlier.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/VNDA_jpg_66bd88803d.webp" alt="VNDA.jpg" width="922" height="88"><figcaption>&nbsp;</figcaption></figure>One bullish user sees strong buy at this level, stating that the motion sickness drug approval is a much bigger news than today's update.<stembedurl>https://stocktwits.com/pablo4/message/641232419</stembedurl>Over the past one year, <a href="https://stocktwits.com/symbol/VNDA">VNDA shares</a> have gained around 52%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game, on September 05, 2025, at Comerica Park in Detroit, Michigan. 

Invesco NASDAQ Future Gen 200 ETF

SPDR SSGA US Small Cap Low Volatility Index ETF

Vanda Pharmaceuticals Inc

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$154.86
Prev Close	$155.56
Open	$154.44
Dividend Yield	N/A
50-Day Moving Average	$154.22
Beta	N/A
Avg. Volume	5,823.34
PE Ratio	N/A

52-Week High	$163.75
52-Week Low	$124.22
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

SMLV Fundamentals